These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19758760)

  • 1. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
    Custodio A; Puente J; Sastre J; Díaz-Rubio E
    Cancer Treat Rev; 2009 Dec; 35(8):676-84. PubMed ID: 19758760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional chemotherapy of advanced pancreatic cancer.
    Giuliani F; Di Maio M; Colucci G; Perrone F
    Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
    Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
    Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
    Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
    Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
    Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    Future Oncol; 2008 Feb; 4(1):41-50. PubMed ID: 18240999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
    Gill S; Ko YJ; Cripps C; Beaudoin A; Dhesy-Thind S; Zulfiqar M; Zalewski P; Do T; Cano P; Lam WYH; Dowden S; Grassin H; Stewart J; Moore M
    J Clin Oncol; 2016 Nov; 34(32):3914-3920. PubMed ID: 27621395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
    Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
    J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line treatment for pancreatic cancer.
    Kaddis N; Saif MW
    JOP; 2014 Jul; 15(4):344-7. PubMed ID: 25076339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
    Péron J; Roy P; Conroy T; Desseigne F; Ychou M; Gourgou-Bourgade S; Stanbury T; Roche L; Ozenne B; Buyse M
    Oncotarget; 2016 Dec; 7(50):82953-82960. PubMed ID: 27765912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
    Oettle H; Riess H; Stieler JM; Heil G; Schwaner I; Seraphin J; Görner M; Mölle M; Greten TF; Lakner V; Bischoff S; Sinn M; Dörken B; Pelzer U
    J Clin Oncol; 2014 Aug; 32(23):2423-9. PubMed ID: 24982456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What options are available for refractory pancreatic cancer?
    Choi M; Kim R; Saif MW
    JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
    Petrelli F; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
    Rev Recent Clin Trials; 2010 Jan; 5(1):43-56. PubMed ID: 20205687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.